Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MB01
- Development stage
- Unknown
- Lead developer
- mAbxience
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MB01 (also known as RTXM83) is a biosimilar monoclonal antibody to rituximab, developed by mAbxience. It targets the CD20 antigen, a protein primarily expressed on the surface of B lymphocytes. Upon binding to CD20, MB01 induces B-cell depletion through several mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and the induction of apoptosis. MB01 is approved for the treatment of B-cell malignancies, specifically non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). First launched in 2014, it was the first biosimilar monoclonal antibody developed in South America and has demonstrated clinical equivalence to the reference product, Rituxan/MabThera.
- Brand names
- NovexKixun
- Other names
- rituximab biosimilarmAbxience rituximab
02
Targets
Beyond the preview
Go deeper on MB01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MB01.